# Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics

> **NCT02579434** · PHASE1 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 102 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Midazolam I.V.

## Key facts

- **NCT ID:** NCT02579434
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-05
- **Final completion:** 2016-04
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02579434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02579434, "Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02579434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*